Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Oxytocin is normally administered following delivery in pregnant patients to reduce postpartum bleeding by increasing uterine tone. It is unclear whether the use of intravenous oxytocin alters coagulation in pregnant patients. The purpose of the in-vitro study is to assess the coagulation changes of oxytocin in blood samples from pregnant patients using thromboelastrography (TEG). TEG is a point-of-care device which measures the viscoelastic properties of clot formation, and can provide rapid and detailed information about coagulation changes. We aim to collect blood samples from pregnant patients to assess the in-vitro effects of synthetic oxytocin on coagulation using TEG.
All obstetric patients presenting for elective induction of labor or elective Cesarean delivery will be informed about the study prior to and on admission to the labor and delivery unit. Admission blood sampling will take place by venepuncture for the following analysis:TEG, PT, PTT, INR, Hct, Platelet count.The results of oxytocin influence on thromboelastogram parameters will be compared to a control. The control is an aliquot of parturient blood with no added oxytocin. Thromboelastography will be used to assess coagulation changes between control samples and blood samples with added oxytocin. The results will not be used to influence clinical management of any case.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| All participants | For each patient, 1 solution with citrated whole blood (control) and 3 solutions with citrated whole blood and exogenous oxytocin were prepared in separate vials using micropipettes as follows: Citrated whole blood 1mL + 23μU oxytocin: final exogenous oxytocin concentration=22.5 μU/mL Citrated whole blood 1mL + 31μU oxytocin: final exogenous oxytocin concentration=30.1μU/mL Citrated whole blood 1mL + 34μU oxytocin: final exogenous oxytocin concentration=32.9μU/mL After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Final exogenous oxytocin concentration=22.5 μU/mL | Drug | Citrated whole blood 1mL + 23μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation. |
| Measure | Description | Time Frame |
|---|---|---|
| r Time | thromboelastographic indices - reaction time (normal range, 5-10 min) | 6 months |
| k Time | thromboelastographic indices - clot formation time (normal range, 1-3 min) | 6 months |
| Alpha Angle | thromboelastographic - alpha angle = clot formation rate (normal range, 53 degress to 72 degrees) | 6 months |
| MA | thromboelastographic indices - maximum amplitude (normal range, 50-70 mm) | 6 months |
| MRTG | thromboelastographic indices - maximum rate of thrombus generation (normal range, 5-17 mm/min) | 6 months |
| Tmax | thromboelastographic indices - time to initiation of clot formation plus time to achieve maximum rate of clot strength development (normal range, 6-12 min) | 6 months |
| TTG | thromboelastographic indices - total thrombus generation (normal range, 584-796 mm) | 6 months |
Not provided
Not provided
Inclusion Criteria:All obstetric patients with singleton pregnancies admitted to the labor and delivery unit at Lucile Packard Childrens Hospital awaiting elective induction of labor or elective Cesarean delivery. We will select 25 healthy ASA 1 patients with singleton pregnancies who are scheduled for uncomplicated elective induction of labor. Gestational age equal to or greater than 37 weeks.
Exclusion Criteria:Patients with underlying coagulation disorders. Patients with thrombocytopenia. Patients with pregnancy-induced hypertension, pre-eclampsia. Patients admitted for non-elective cesarean section. Patients in active labor. Patients requiring the following medications prior to surgery: NSAIDS, aspirin, anticoagulants.
Patients with significant obstetric or medical disease. No patients <18 years of age will be recruited.
Not provided
Not provided
healthy pregnant patients awaiting elective induction of labor or cesarean delivery.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Alexander J Butwick | Stanford University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94305 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | All Participants | For each patient, 1 solution with citrated whole blood (control) and 3 solutions with citrated whole blood and exogenous oxytocin were prepared in separate vials using micropipettes as follows: Citrated whole blood 1mL + 23μU oxytocin: final exogenous oxytocin concentration=22.5 μU/mL Citrated whole blood 1mL + 31μU oxytocin: final exogenous oxytocin concentration=30.1μU/mL Citrated whole blood 1mL + 34μU oxytocin: final exogenous oxytocin concentration=32.9μU/mL After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Venous blood
|
|
| Final exogenous oxytocin concentration=30.1μU/mL | Drug | Citrated whole blood 1mL + 31μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation. |
|
|
| Final exogenous oxytocin concentration=32.9μU/mL | Drug | Citrated whole blood 1mL + 34μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation. |
|
|
| Oxytocin Infusion 1: 22.5 μU/mL |
|
| Oxytocin Infusion 2: 30.1μU/mL |
|
| Oxytocin Infusion 3: 32.9μU/mL |
|
| Oxytocin: 0 μU/mL |
|
| COMPLETED |
|
| NOT COMPLETED |
|
All blood samples for this study were taken from a total cohort of 25 patients
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | All Participants | For each patient, 1 solution with citrated whole blood (control) and 3 solutions with citrated whole blood and exogenous oxytocin were prepared in separate vials using micropipettes as follows: Citrated whole blood 1mL + 23μU oxytocin: final exogenous oxytocin concentration=22.5 μU/mL Citrated whole blood 1mL + 31μU oxytocin: final exogenous oxytocin concentration=30.1μU/mL Citrated whole blood 1mL + 34μU oxytocin: final exogenous oxytocin concentration=32.9μU/mL After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Our cohort comprised healthy adult pregnant women | Count of Participants | Participants |
| |||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | r Time | thromboelastographic indices - reaction time (normal range, 5-10 min) | Posted | Mean | Standard Deviation | minutes | 6 months |
|
|
| ||||||||||||||||||||||||||||||||||||
| Primary | k Time | thromboelastographic indices - clot formation time (normal range, 1-3 min) | Posted | Mean | Standard Deviation | minutes | 6 months |
|
| |||||||||||||||||||||||||||||||||||||
| Primary | Alpha Angle | thromboelastographic - alpha angle = clot formation rate (normal range, 53 degress to 72 degrees) | Posted | Mean | Standard Deviation | degrees | 6 months |
|
| |||||||||||||||||||||||||||||||||||||
| Primary | MA | thromboelastographic indices - maximum amplitude (normal range, 50-70 mm) | Posted | Mean | Standard Deviation | mm | 6 months |
|
| |||||||||||||||||||||||||||||||||||||
| Primary | MRTG | thromboelastographic indices - maximum rate of thrombus generation (normal range, 5-17 mm/min) | Posted | Mean | Standard Deviation | mm/min | 6 months |
|
| |||||||||||||||||||||||||||||||||||||
| Primary | Tmax | thromboelastographic indices - time to initiation of clot formation plus time to achieve maximum rate of clot strength development (normal range, 6-12 min) | Posted | Mean | Standard Deviation | minutes | 6 months |
|
| |||||||||||||||||||||||||||||||||||||
| Primary | TTG | thromboelastographic indices - total thrombus generation (normal range, 584-796 mm) | Posted | Mean | Standard Deviation | mm | 6 months |
|
|
1 year
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 22.5 μU/mL Exogenous Oxytocin | thromboelastography: TEG was performed on kaolin-activated citrated blood samples | 0 | 25 | 0 | 25 | ||
| EG001 | 30.1 μU/mL Exogenous Oxytocin | thromboelastography: TEG was performed on kaolin-activated citrated blood samples | 0 | 25 | 0 | 25 | ||
| EG002 | 32.9 μU/mL Exogenous Oxytocin | thromboelastography: TEG was performed on kaolin-activated citrated blood samples | 0 | 25 | 0 | 25 | ||
| EG003 | 0 μU/mL Exogenous Oxytocin | Thromboelastography on native blood sample. | 0 | 25 | 0 | 25 |
Not provided
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Alexander Butwick | Stanford University School of Medicine | (650) 736-8513 | ajbut@stanford.edu |
| Title | Measurements |
|---|---|
|
| Exogenous oxytocin 0 |
|
|
|
|
|
|
|